Literature DB >> 20309868

Angiogenesis and the persistence of inflammation in a rat model of proliferative synovitis.

Sadaf Ashraf1, Paul I Mapp, David A Walsh.   

Abstract

OBJECTIVE: To determine whether blood vessel growth at the onset of resolving synovitis leads to its subsequent persistence and whether inhibiting this angiogenesis at the onset of persistent inflammation leads to its subsequent resolution.
METHODS: Inflammation and angiogenesis were induced by injection of 0.03% carrageenan and/or 6 pmoles of fibroblast growth factor 2 (FGF-2) into rat knees. A brief treatment with the angiogenesis inhibitor PPI-2458 (5 mg/kg orally on alternate days) was administered 1 day before and up to 3 days after synovitis induction. Controls comprised naive and vehicle-treated rats. Synovial angiogenesis was measured using the endothelial cell proliferation index, and inflammation was determined by measuring joint swelling and macrophage percentage area. Data are presented as the geometric mean (95% confidence interval).
RESULTS: Intraarticular injection of 0.03% carrageenan into rat knees produced acute synovitis, which was not associated with synovial angiogenesis and which resolved within 29 days. Injection of FGF-2 (6 pmoles) induced synovial angiogenesis without significant synovitis. Stimulation of angiogenesis with FGF-2 at the time of carrageenan injection was followed by synovitis that persisted for 29 days. Persistence of carrageenan/FGF-2-induced synovitis was prevented by systemic administration of 3 doses of the angiogenesis inhibitor PPI-2458 during the acute phase.
CONCLUSION: Our findings indicate that conversion of acute inflammation to chronic inflammation may be due to the stimulation of angiogenesis, and brief antiangiogenic treatment during the acute phase of synovitis may prevent its subsequent progression. Clinical studies will be needed to determine whether brief antiangiogenic treatment may reduce the burden of inflammatory joint diseases such as rheumatoid arthritis by facilitating the resolution of early synovitis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20309868     DOI: 10.1002/art.27462

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  17 in total

Review 1.  Mechanisms and targets of angiogenesis and nerve growth in osteoarthritis.

Authors:  Paul I Mapp; David A Walsh
Journal:  Nat Rev Rheumatol       Date:  2012-05-29       Impact factor: 20.543

Review 2.  Calcitonin gene-related peptide in the joint: contributions to pain and inflammation.

Authors:  David A Walsh; Paul I Mapp; Sara Kelly
Journal:  Br J Clin Pharmacol       Date:  2015-07-22       Impact factor: 4.335

3.  Orally active fumagillin analogues: transformations of a reactive warhead in the gastric environment.

Authors:  Christopher C Arico-Muendel; Heather Blanchette; Dennis R Benjamin; Teresa M Caiazzo; Paolo A Centrella; Jennifer DeLorey; Elisabeth G Doyle; Steven R Johnson; Matthew T Labenski; Barry A Morgan; Gary O'Donovan; Amy A Sarjeant; Steven Skinner; Charles D Thompson; Sarah T Griffin; William Westlin; Kerry F White
Journal:  ACS Med Chem Lett       Date:  2013-02-22       Impact factor: 4.345

4.  A role for the sensory neuropeptide calcitonin gene-related peptide in endothelial cell proliferation in vivo.

Authors:  Paul I Mapp; Daniel F McWilliams; Matthew J Turley; Edward Hargin; David A Walsh
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

5.  Characterization of degenerative human facet joints and facet joint capsular tissues.

Authors:  J-S Kim; M H Ali; F Wydra; X Li; J L Hamilton; H S An; G Cs-Szabo; S Andrews; M Moric; G Xiao; J H-C Wang; Di Chen; J M Cavanaugh; H-J Im
Journal:  Osteoarthritis Cartilage       Date:  2015-06-25       Impact factor: 6.576

Review 6.  The future of osteoarthritis therapeutics: emerging biological therapy.

Authors:  A Mobasheri
Journal:  Curr Rheumatol Rep       Date:  2013-12       Impact factor: 4.592

7.  Patients with rheumatoid arthritis in clinical remission and ultrasound-defined active synovitis exhibit higher disease activity and increased serum levels of angiogenic biomarkers.

Authors:  Julio Ramírez; Virginia Ruíz-Esquide; Isaac Pomés; Raquel Celis; Andrea Cuervo; Ma Victoria Hernández; Jaume Pomés; José L Pablos; Raimon Sanmartí; Juan D Cañete
Journal:  Arthritis Res Ther       Date:  2014-01-08       Impact factor: 5.156

8.  Augmented pain behavioural responses to intra-articular injection of nerve growth factor in two animal models of osteoarthritis.

Authors:  Sadaf Ashraf; Paul Ian Mapp; James Burston; Andrew John Bennett; Victoria Chapman; David Andrew Walsh
Journal:  Ann Rheum Dis       Date:  2013-07-13       Impact factor: 19.103

9.  Dual Therapeutic Action of a Neutralizing Anti-FGF2 Aptamer in Bone Disease and Bone Cancer Pain.

Authors:  Ling Jin; Yosuke Nonaka; Shin Miyakawa; Masatoshi Fujiwara; Yoshikazu Nakamura
Journal:  Mol Ther       Date:  2016-08-10       Impact factor: 11.454

10.  Selective inhibition of tropomyosin-receptor-kinase A (TrkA) reduces pain and joint damage in two rat models of inflammatory arthritis.

Authors:  Sadaf Ashraf; Karyn S Bouhana; Jed Pheneger; Steven W Andrews; David A Walsh
Journal:  Arthritis Res Ther       Date:  2016-05-04       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.